What is Takotsubo (stress) cardiomyopathy syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Takotsubo syndrome, also known as stress cardiomyopathy or broken heart syndrome, is a temporary heart condition that mimics a heart attack but is caused by emotional or physical stress rather than blocked arteries, with a substantial incidence of life-threatening complications necessitating close monitoring and early intervention in unstable patients 1.

Key Characteristics

  • The condition is characterized by acute, usually reversible left ventricular (LV) dysfunction in the absence of significant coronary artery disease (CAD), usually triggered by acute emotional or physical stress 1.
  • It can present with symptoms similar to those of acute coronary syndrome and may have transiently elevated cardiac enzymes such as cardiac troponin 1.
  • The characteristic ballooning of the left ventricle resembles a Japanese octopus trap (tako-tsubo), although other diverse ventricular contraction patterns have been defined by cardiovascular imaging 1.

Risk Factors and Complications

  • Parameters predicting adverse in-hospital outcome include physical trigger, acute neurologic or psychiatric diseases, initial troponin >10 upper reference limit, and admission LVEF <45% 1.
  • Male patients have an up to three-fold increased rate of death and major adverse cardiac and cerebrovascular events (MACCE) and more often had an underlying critical illness, further contributing to the higher mortality 1.
  • Complications included cardiac death, pump failure, sustained ventricular tachycardia or ventricular fibrillation, and advanced atrioventricular block 1.

Treatment and Outcome

  • Treatment focuses on supportive care while the heart recovers, typically including ACE inhibitors, beta-blockers, and aspirin for 1-3 months until heart function normalizes 1.
  • In severe cases with heart failure symptoms, diuretics like furosemide may be needed 1.
  • Most patients recover completely within 1-3 months with no permanent heart damage, although recurrence is possible (10-15% of cases) 1.

From the Research

Definition and Characteristics of Takotsubo Syndrome

  • Takotsubo syndrome (TS) is an acute heart failure syndrome characterized by a sudden weakening of the heart muscle, usually triggered by physical or emotional stress 2, 3, 4, 5, 6.
  • It is often misdiagnosed as acute coronary syndrome due to similar symptoms and electrocardiographic changes 3, 5.
  • TS is self-limiting in most cases but can result in life-threatening complications, including cardiogenic shock, pulmonary edema, thromboembolism, and arrhythmias 2, 5.

Diagnosis and Management

  • Diagnosis of TS can be made using Mayo diagnostic criteria, and cardiac imaging is critical for a timely diagnosis 3, 5.
  • Management of TS should focus on careful monitoring of ECG and hemodynamics, and on preventing and treating complications 2.
  • Treatment may include beta-blockers, angiotensin-converting enzyme inhibitors, and statins, but the use of inotropic agents is generally contraindicated, especially in patients with left ventricular outflow tract obstruction (LVOTO) 2, 3, 4.
  • Mechanical assist devices should be considered early for patients with TS who develop cardiogenic shock with signs of end-organ hypo-perfusion 2.

Pathophysiology and Prognosis

  • The mechanism behind TS remains elusive, but multiple theories have been proposed, including an acute increase in left ventricular afterload, multi-vessel coronary vasospasm, coronary endothelial microvascular dysfunction, and inflammation 5, 6.
  • TS has substantial morbidity and mortality, with a probability of all-cause mortality of 2.5% after 30 days and 16.6% after 6 years 4.
  • Certain pharmacological interventions, such as angiotensin-converting enzyme inhibitors and statins, may be associated with decreased long-term mortality, while others, such as inotropes and diuretics, may be associated with increased 30-day mortality 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.